Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects

European Neuropsychopharmacology

Volumn 23, Issue 8, 2013, Pages 852-864

  Muguruza, Carolina ^a,c   Moreno, José L ^d   Umali, Adrienne ^d   Callado, Luis F ^a,b,c   Meana, J Javier ^a,b,c   González Maeso, Javier ^d  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Postmortem human brain; Radioligand binding; Schizophrenia; Serotonin; Serotonin 5 HT2A receptor; Suicide

Indexed keywords

ALTANSERIN; KETANSERIN; LYSERGIDE; SEROTONIN 2A RECEPTOR;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN CONFORMATION; SCHIZOPHRENIA; SUICIDAL BEHAVIOR;

POSTMORTEM HUMAN BRAIN; RADIOLIGAND BINDING; SCHIZOPHRENIA; SEROTONIN; SEROTONIN 5-HT2A RECEPTOR; SUICIDE;

AMPHETAMINES; ANIMALS; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FRONTAL LOBE; HUMANS; KETANSERIN; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEURONS; PREFRONTAL CORTEX; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2A; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; SUICIDE; UP-REGULATION;

EID: 84881665340     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.10.006     Document Type: Article

References (50)

1. Anastasopoulos G., Photiades H. Effects of LSD-25 on relatives of schizophrenic patients. J. Ment. Sci. 1962, 108:95-98.
2. Arranz B., Eriksson A., Mellerup E., Plenge P., Marcusson J. Brain 5-HT1A, 5-HT1D, and 5-HT2 receptors in suicide victims. Biol. Psychiatry 1994, 35:457-463.
3. Bennett J.P., Enna S.J., Bylund D.B., Gillin J.C., Wyatt R.J., Snyder S.H. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch. Gen. Psychiatry 1979, 36:927-934.
4. Burnet P.W., Eastwood S.L., Harrison P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996, 15:442-455.
5. Cheetham S.C., Crompton M.R., Katona C.L., Horton R.W. Brain 5-HT2 receptor binding sites in depressed suicide victims. Brain Res. 1988, 443:272-280.
6. Crow T.J., Cross A.J., Cooper S.J., Deakin J.F., Ferrier I.N., Johnson J.A., Joseph M.H., Owen F., Poulter M., Lofthouse R., et al. Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 1984, 23:1561-1569.
7. Davidson M., Harvey P.D., Powchik P., Parrella M., White L., Knobler H.Y., Losonczy M.F., Keefe R.S., Katz S., Frecska E. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am. J. Psychiatry 1995, 152:197-207.
8. Dean B. The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J. Neurochem. 2003, 85:1-13.
9. Dean B., Crossland N., Boer S., Scarr E. Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia. Schizophr. Res. 2008, 104:185-197.
10. Dean B., Hayes W. Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr. Res. 1996, 21:133-139.
11. Dean B., Hayes W., Hill C., Copolov D. Decreased serotonin2A receptors in Brodmann's area 9 from schizophrenic subjects. A pathological or pharmacological phenomenon?. Mol. Chem. Neuropathol. 1998, 34:133-145.
12. Dean B., Hayes W., Opeskin K., Naylor L., Pavey G., Hill C., Keks N., Copolov D.L. Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behav. Brain Res. 1996, 73:169-175.
13. Dean B., Hussain T., Hayes W., Scarr E., Kitsoulis S., Hill C., Opeskin K., Copolov D.L. Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J. Neurochem. 1999, 72:1593-1599.
14. Deep-Soboslay A., Akil M., Martin C.E., Bigelow L.B., Herman M.M., Hyde T.M., Kleinman J.E. Reliability of psychiatric diagnosis in postmortem research. Biol. Psychiatry 2005, 57:96-101.
15. Egan C.T., Herrick-Davis K., Teitler M. Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J. Pharmacol. Exp. Ther. 1998, 286:85-90.
16. Fribourg M., Moreno J.L., Holloway T., Provasi D., Baki L., Mahajan R., Park G., Adney S.K., Hatcher C., Eltit J.M., Ruta J.D., Albizu L., Li Z., Umali A., Shim J., Fabiato A., Mackerell A.D., Brezina V., Sealfon S.C., Filizola M., Gonzalez-Maeso J., Logothetis D.E. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 2011, 147:1011-1023.
17. Gonzalez-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., Lopez-Gimenez J.F., Zhou M., Okawa Y., Callado L.F., Milligan G., Gingrich J.A., Filizola M., Meana J.J., Sealfon S.C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452:93-97.
18. Gonzalez-Maeso J., Sealfon S.C. Psychedelics and schizophrenia. Trends Neurosci. 2009, 32:225-232.
19. Gouzoulis-Mayfrank E., Heekeren K., Neukirch A., Stoll M., Stock C., Obradovic M., Kovar K.A. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 2005, 38:301-311.
20. 3H]ketanserin binding in the human brain postmortem: effect of suicide. Brain Res. 1990, 507:208-215.
21. Gross-Isseroff R., Salama D., Israeli M., Biegon A. Autoradiographic analysis of age-dependent changes in serotonin 5-HT2 receptors of the human brain postmortem. Brain Res. 1990, 519:223-227.
22. Gurevich E.V., Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry 1997, 42:529-545.
23. Hermle L., Funfgeld M., Oepen G., Botsch H., Borchardt D., Gouzoulis E., Fehrenbach R.A., Spitzer M. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol. Psychiatry 1992, 32:976-991.
24. Hoch P.H., Cattell J.P., Pennes H.H. Effects of mescaline and lysergic acid (d-LSD-25). Am. J. Psychiatry 1952, 108:579-584.
25. Hof P.R., Young W.G., Bloom F.E., Belichenko P.V., Celio M.R. Comparative Cytoarchitectonic Atlas of the C57BL/6 and 129/Sv Mouse Brains 2000, Elsevier., Amsterdam, The Netherlands.
26. Huot P., Johnston T.H., Darr T., Hazrati L.N., Visanji N.P., Pires D., Brotchie J.M., Fox S.H. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov. Disord. 2010, 25:1399-1408.
27. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993, 8:315-336.
28. Kang K., Huang X.F., Wang Q., Deng C. Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia-a postmortem study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:867-871.
29. Kurita M., Holloway T., Garcia-Bea A., Kozlenkov A., Friedman A.K., Moreno J.L., Heshmati M., Golden S.A., Kennedy P.J., Takahashi N., Dietz D.M., Mocci G., Gabilondo A.M., Hanks J., Umali A., Callado L.F., Gallitano A.L., Neve R.L., Shen L., Buxbaum J.D., Han M.H., Nestler E.J., Meana J.J., Russo S.J., Gonzalez-Maeso J. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat. Neurosci. 2012, 15:1245-1254.
30. Laruelle M., Abi-Dargham A., Casanova M.F., Toti R., Weinberger D.R., Kleinman J.E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch. Gen. Psychiatry 1993, 50:810-818.
31. Lowther S., De Paermentier F., Crompton M.R., Katona C.L., Horton R.W. Brain 5-HT2 receptors in suicide victims: violence of death, depression and effects of antidepressant treatment. Brain Res. 1994, 642:281-289.
32. 3H]-ketanserin binding sites in different psychiatric disorders. Neurochem. Int. 2003, 42:511-516.
33. Matsumoto I., Inoue Y., Iwazaki T., Pavey G., Dean B. 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. Neurosci. Lett. 2005, 379:164-168.
34. Millan M.J., Marin P., Bockaert J., Mannoury la Cour C. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol. Sci. 2008, 29:454-464.
35. Mita T., Hanada S., Nishino N., Kuno T., Nakai H., Yamadori T., Mizoi Y., Tanaka C. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol. Psychiatry 1986, 21:1407-1414.
36. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10:79-104.
37. Moses-Kolko E.L., Price J.C., Shah N., Berga S., Sereika S.M., Fisher P.M., Coleman R., Becker C., Mason N.S., Loucks T., Meltzer C.C. Age, sex, and reproductive hormone effects on brain serotonin-1A and serotonin-2A receptor binding in a healthy population. Neuropsychopharmacology 2011, 36:2729-2740.
38. Oquendo M.A., Russo S.A., Underwood M.D., Kassir S.A., Ellis S.P., Mann J.J., Arango V. Higher postmortem prefrontal 5-HT2A receptor binding correlates with lifetime aggression in suicide. Biol. Psychiatry 2006, 59:235-243.
39. Owen F., Cross A.J., Crow T.J., Deakin J.F., Ferrier I.N., Lofthouse R., Poulter M. Brain 5-HT-2 receptors and suicide. Lancet 1983, 2:1256.
40. Quednow B.B., Kometer M., Geyer M.A., Vollenweider F.X. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology 2011, 37:630-640.
41. Rajkowska G., Goldman-Rakic P.S. Cytoarchitectonic definition of prefrontal areas in the normal human cortex: II. Variability in locations of areas 9 and 46 and relationship to the Talairach coordinate system. Cereb. Cortex 1995, 5:323-337.
42. Rasmussen H., Erritzoe D., Andersen R., Ebdrup B.H., Aggernaes B., Oranje B., Kalbitzer J., Madsen J., Pinborg L.H., Baare W., Svarer C., Lublin H., Knudsen G.M., Glenthoj B. Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry 2010, 67:9-16.
43. Reynolds G.P., Rossor M.N., Iversen L.L. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J. Neural Transm. Suppl. 1983, 18:273-277.
44. Rosel P., Arranz B., San L., Vallejo J., Crespo J.M., Urretavizcaya M., Navarro M.A. Altered 5-HT(2A) binding sites and second messenger inositol trisphosphate (IP(3)) levels in hippocampus but not in frontal cortex from depressed suicide victims. Psychiatry Res. 2000, 99:173-181.
45. Stockmeier C.A., Dilley G.E., Shapiro L.A., Overholser J.C., Thompson P.A., Meltzer H.Y. Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 1997, 16:162-173.
46. Turecki G., Briere R., Dewar K., Antonetti T., Lesage A.D., Seguin M., Chawky N., Vanier C., Alda M., Joober R., Benkelfat C., Rouleau G.A. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am. J. Psychiatry 1999, 156:1456-1458.
47. Underwood M.D., Mann J.J., Huang Y.Y., Arango V. Family history of alcoholism is associated with lower 5-HT2A receptor binding in the prefrontal cortex. Alcohol Clin. Exp. Res. 2008, 32:593-599.
48. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Babler A., Vogel H., Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998, 9:3897-3902.
49. Whitaker P.M., Crow T.J., Ferrier I.N. Tritiated LSD binding in frontal cortex in schizophrenia. Arch. Gen. Psychiatry 1981, 38:278-280.
50. Young B.G. A phenomenological comparison of LSD and schizophrenic states. Br. J. Psychiatry 1974, 124:64-74.